# Graham H. Jackson

Source: https://onco.cc/people/graham-jackson/  
OnCo record `graham-jackson` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led Myeloma XI, the 4,000-patient UK trial that proved lenalidomide maintenance extends survival after transplant.

## Summary

Graham Jackson was chief investigator of Myeloma XI, the largest myeloma trial ever run, which showed lenalidomide maintenance improves progression-free and overall survival in transplant-eligible patients and defined the benefit of triplet induction, and of the earlier Myeloma IX trial. He chairs the UK Myeloma Research Alliance and leads the RADAR trial of MRD-guided treatment.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: myeloma; maintenance; uk
- Role: Professor of Clinical Haematology, Newcastle University; Consultant, Freeman Hospital
- Specialisms: Multiple myeloma; Maintenance therapy; Large pragmatic trials; Transplantation

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Jackson%20GH%5BAuthor%5D%20myeloma%20XI

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- institutions: [Newcastle Cancer Centre / Northern Centre for Cancer Care](https://onco.cc/institutions/newcastle-cancer-centre/)

---
JSON: https://onco.cc/api/v1/entities/graham-jackson.json